Washington Trust Bank’s VanEck Biotech ETF BBH Stock Holding History

Washington Trust Bank’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-200	Closed	-$21K	–	816
2016 Q1	$21K	Buy	+200	New	+$20.9K	0.01%	494

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Aspiriant LLC Los Angeles, California $3.51B AUM 13.98% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Washington Trust Bank's BBH Position: Q2 2016 in Review

Washington Trust Bank sold out of VanEck Biotech ETF (BBH) in Q2 2016, closing a stake of 200 shares — an estimated $21K sold.

Washington Trust Bank first reported a position in BBH in Q1 2016 and held it in 1 quarter. The position peaked at $21K in Q1 2016. 78 funds tracked by Wall St. Rank hold BBH as of Q2 2016.

Washington Trust Bank reported no remaining VanEck Biotech ETF position as of Q2 2016 after selling out during the quarter.
Washington Trust Bank sold 200 VanEck Biotech ETF shares in Q2 2016, an estimated $21K.
Washington Trust Bank first reported a position in VanEck Biotech ETF in Q1 2016 and held it in 1 quarter.
Washington Trust Bank's VanEck Biotech ETF position peaked at $21K in Q1 2016.
78 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2016.

Based on Washington Trust Bank's 13F filing for Q2 2016, filed 7 Jul 2016.